In order to help increase pet owner compliance, Rimifin, a non-steroidal anti-inflammatory drug marketed by Vétoquinol, has now got a new flavouring.
Pet owner compliance is critical to ensuring effective and continuing treatment in chronic conditions such as osteoarthritis. To help increase compliance, Rimifin, a NSAID marketed by Vétoquinol, has now got a new flavouring.
Rimifin product manager Robert Simpson said: “Pet owner compliance and involvement in chronic pain situations is critical to ensuring effective long term treatment. Ease of administration is also very important in this setting.
“The addition of this flavouring to this popular and cost effective NSAID will help to ensure that administration to the patient is as easy as possible for pet owners and vets.”
Rimifin is a non-steroidal anti-inflammatory drug (NSAID) which contains carprofen (POM-V).
- For further information contact your Vétoquinol territory manager or call 01280 825424.